ReviewHormones (Athens, Greece)2026
PRKAR1A-related acrodysostosis with partial growth hormone deficiency: 18-month response to recombinant human growth hormone.
Review in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo describe the 18-month auxological response to recombinant human growth hormone (rhGH) therapy in a pediatric patient with genetically confirmed PRKAR1A-related acrodysostosis and partial growth hormone deficiency (GHD).
methodsA 3-year-9-month-old boy with genetically confirmed PRKAR1A-related acrodysostosis underwent comprehensive endocrine evaluation due to progressive growth deceleration. Growth hormone (GH) secretion was assessed using two pharmacological stimulation tests (glucagon and L-dopa). rhGH therapy was initiated and titrated based on clinical and biochemical response, with serial auxological and biochemical follow-up over 18 months.
resultsAt presentation (3 years 9 months), height was - 2.92 SDS with a growth velocity of 3 cm/year over the preceding year. Two stimulation tests demonstrated peak GH levels of 8 ng/mL and 5.5 ng/mL, consistent with partial GHD. Brain MRI revealed mild anterior pituitary hypoplasia. After 18 months of rhGH therapy, height increased from 89 cm to 103.5 cm and height SDS improved from - 2.92 to - 1.52 (Δ + 1.40 SDS), with a first-year height velocity of 11 cm/year. Bone age advanced from 2 years 8 months at treatment initiation to 4 years 6 months at 18 months. Serum IGF-1 increased while remaining within the age-adjusted laboratory reference range, and no adverse effects were observed during follow-up.
conclusionTo our knowledge, this represents the second published pediatric case of type 1 acrodysostosis with documented partial GHD treated with rhGH. The marked auxological response over 18 months supports the concept that central GH axis impairment may coexist with the intrinsic skeletal pathology of the disorder in some patients.
Indexed as
Identifiers
42449097What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.